CIPN is a common adverse effect of several cancer therapies including taxanes and platinum drugs. Symptoms include decreased sensation and tingling of the hands and feet, severe pain, numbness and muscle weakness, all of which can occur during cancer treatment, and frequently persist after chemotherapy has ended.
The classification of Chemotherapy Induced Peripheral Neuropathy Treatment includes Calcium channel α2-delta ligands, Antidepressants, Opioids and Other Drugs. And the proportion of Opioids in 2020 is about 27%, and the proportion is in decreasing trend from 2013 to 2020.
Chemotherapy Induced Peripheral Neuropathy Treatment is widely used for CIPN cause by Platinum Agents, Taxanes, Vinca Alkaloids and Others. The most proportion of Chemotherapy Induced Peripheral Neuropathy Treatment is used in Platinum Agents, and the proportion in 2020 is 42%.
North America is the largest sales place, with a sales market share nearly 41% in 2020. Following North America, Europe is the second largest sales place with the sales market share of 27%.
The global Chemotherapy Induced Peripheral Neuropathy Treatment market is valued at 1300 million US$ in 2020 and will reach 2150 million US$ by the end of 2026, growing at a CAGR of 6.5% during 2021-2026. The objectives of this study are to define, segment, and project the size of the Chemotherapy Induced Peripheral Neuropathy Treatment market based on company, product type, end user and key regions.
This report studies the global market size of Chemotherapy Induced Peripheral Neuropathy Treatment in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Chemotherapy Induced Peripheral Neuropathy Treatment in these regions.
This research report categorizes the global Chemotherapy Induced Peripheral Neuropathy Treatment market by top players/brands, region, type and end user. This report also studies the global Chemotherapy Induced Peripheral Neuropathy Treatment market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
This report covers the present status and the future prospects of the global Chemotherapy Induced Peripheral Neuropathy Treatment market for 2015-2026.
The report offers detailed coverage of Chemotherapy Induced Peripheral Neuropathy Treatment industry and main market trends. The market research includes historical and forecast market data, demand, application details, price trends, and company shares of the leading Chemotherapy Induced Peripheral Neuropathy Treatment by geography. The report splits the market size, by volume and value, on the basis of application type and geography.
And in this report, we analyze global market from 5 geographies: Asia-Pacific[China, Southeast Asia, India, Japan, Korea, Western Asia], Europe[Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland], North America[United States, Canada, Mexico], Middle East & Africa[GCC, North Africa, South Africa], South America[Brazil, Argentina, Columbia, Chile, Peru].
Key Companies
Calcium Channel α2-delta Ligands, Antidepressants, Opioids, Others,
Market Segment as follows:
Market by Order Type
Calcium Channel α2-delta Ligands
Antidepressants
Opioids
Others
Market size by End User
Platinum Agents
Taxanes
Vinca Alkaloids
Others
market while maintaining their competitive edge over their competitors. The report offers detailed and crucial information to understand the overall market scenario.
By Region
Asia-Pacific[China, Southeast Asia, India, Japan, Korea, Western Asia]
Europe[Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland]
North America[United States, Canada, Mexico]
Middle East & Africa[GCC, North Africa, South Africa]
South America[Brazil, Argentina, Columbia, Chile, Peru]
The research provides answers to the following key questions:
• What is the estimated growth rate and market share and size of the Chemotherapy Induced Peripheral Neuropathy Treatment market for the forecast period 2021 - 2026?
• What are the driving forces in the Chemotherapy Induced Peripheral Neuropathy Treatment market for the forecast period 2021 - 2026?
• Who are the prominent market players and how have they gained a competitive edge over other competitors?
• What are the market trends influencing the progress of the Chemotherapy Induced Peripheral Neuropathy Treatment industry worldwide?
• What are the major challenges and threats restricting the progress of the industry?
• What opportunities does the market hold for the prominent market players?
Note – In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.